UK markets closed

Lyra Therapeutics, Inc. (LYRA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.3830+0.0154 (+4.19%)
At close: 04:00PM EDT
0.3879 +0.00 (+1.28%)
After hours: 07:58PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
1,680
1,558
1,363
285
0
Operating expenses
Research development
53,671
48,029
38,797
29,694
12,522
Selling general and administrative
19,748
19,057
17,556
14,206
9,687
Total operating expenses
73,419
67,086
56,353
43,900
22,209
Operating income or loss
-71,739
-65,528
-54,990
-43,615
-22,209
Total other income/expenses net
-
-1,592
-1,316
-
-
Income before tax
-68,818
-62,621
-55,265
-43,513
-22,127
Income tax expense
59
59
13
0
-
Income from continuing operations
-68,877
-62,680
-55,278
-43,513
-22,127
Net income
-68,877
-62,680
-55,278
-43,513
-22,127
Net income available to common shareholders
-68,877
-62,680
-55,278
-43,513
-22,242
Basic EPS
-1.40
-1.26
-1.83
-3.35
-2.59
Diluted EPS
-1.40
-1.26
-1.83
-3.35
-2.59
Basic average shares
43,646
49,804
30,236
12,986
8,590
Diluted average shares
43,646
49,804
30,236
12,986
8,590